Natera, Inc. (NASDAQ:NTRA) Stock Holdings Lowered by abrdn plc

abrdn plc reduced its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 81.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,435 shares of the medical research company's stock after selling 27,841 shares during the period. abrdn plc's holdings in Natera were worth $1,019,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Blue Trust Inc. boosted its stake in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc boosted its position in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after acquiring an additional 166 shares during the last quarter. Covestor Ltd boosted its position in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after acquiring an additional 95 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock worth $55,000 after acquiring an additional 106 shares during the last quarter. Finally, True Wealth Design LLC acquired a new position in Natera during the third quarter valued at approximately $57,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on NTRA. Robert W. Baird boosted their price objective on shares of Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. Sanford C. Bernstein boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. TD Cowen boosted their price objective on shares of Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Finally, Canaccord Genuity Group boosted their price objective on shares of Natera from $165.00 to $180.00 and gave the stock a "buy" rating in a research note on Friday, January 3rd. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $165.88.

Insider Activity at Natera

In other Natera news, Director Gail Boxer Marcus sold 9,682 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the sale, the director now directly owns 9,704 shares of the company's stock, valued at approximately $1,552,445.92. This represents a 49.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 305,454 shares of company stock valued at $51,290,625 over the last ninety days. Corporate insiders own 7.60% of the company's stock.

Natera Stock Up 1.6 %

NTRA traded up $2.66 during trading on Friday, hitting $173.39. The company had a trading volume of 1,571,626 shares, compared to its average volume of 1,340,396. The company has a market cap of $22.89 billion, a PE ratio of -98.52 and a beta of 1.66. The business has a 50-day moving average of $167.75 and a 200-day moving average of $142.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1-year low of $68.03 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analysts' expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm's quarterly revenue was up 63.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.95) earnings per share. As a group, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.